Very happy and proud to share our @JCO_ASCO publication. Accordin to our research no advantage in OS and DFS adding oxaliplatin to adjuvant stage III colorectal cancer in older patients.
https://t.co/G3rgj65fWd
Subcutaneous Immunotherapy in Cancer: Where We Are Now, What It Changes, and What to Watch Next.
Co-authored by @faupe.
Read the full article. https://t.co/2WR6KX6BoN
#ImmunoOnc
Oxaliplatin in Stage II–III CRC: Age Matters
🔹 Stage III, ≤70 yrs → OS benefit
🔹 Stage III, >70 yrs → No OS gain
🔹 Stage II (any age) → No OS benefit
💬 Supports an individualized, age- and stage-adapted approach to adjuvant oxaliplatin use
https://t.co/kEszxn4Mq8
Adjuvant CDK4/6 inhibitors in older patients: safe and effective or to be used with caution? We aimed to answer in our last study I'm very happy to share.
As always special thanks to @JGeriOnc staff.
https://t.co/DoJU3mncvg
Every time they approve a drug based on non-survival endpoint, they give us some excuse. I have collected those excuses. There are seven of them.
In this new column in @Medscape , I and Dr. Sharon Batt, a cancer survivor and regulatory science expert, list these seven arguments and specifically respond to each of them to demonstrate why OS still remains the most patient centric endpoint for cancer drug trials.
Please do read. This is NOT another “surrogates are bad” paper. We specifically address the concerns raised against OS. I hope you’ll be convinced.
https://t.co/KCEmmBudV2
There are just a few days until #ESMO24! We're looking forward to seeing many colleagues and friends. Stop by the #SIOG stand S314 to say hi! Psst. We're offering special ESMO24 discounts on SIOG memberships. Spread the word. See you then!
💉FOLFOX/Xelox + beva vs. 5FU/cape +beva in first line treatment of metastatic CRC in older patients
@JCO_ASCO
➡️Median age 80 and 79
❌No difference in PFS, 10 vs 9.4 mo.
❌No difference in OS, 19.7 vs 21.3 mo.
❌grade ≥3 AEs 69% vs. 52%
❗️~65% left sided and ~36% RAS WT
👉https://t.co/TvtQM19Rc6
@JCOOP_ASCO@ASCO@OncoAlert@BbaharK #cancer #oncology #MedX
Congrats to @faupe and colleagues. Vitamin D supplementation reduce total cancer mortality! Strong evidence for thyroid and renal cancer, highly suggestive evidence for many others. Maybe Vit D is deeply underestimated in oncology treatment and prevention?
https://t.co/UKpLnQhINl